Stock Watch: Regeneron’s Constellation of Ophthalmic Competition
When One Product Loses Exclusivity, Potentially All Market Shares Can Suffer
Executive Summary
The accepted commercial dynamics of a competitive indication in older patients can be disrupted by new entrants with improved profiles, lower priced biosimilar competition and (soon) Medicare price negotiations.